Cassava Sciences Announces New CEO and Governance Changes
Company Announcements

Cassava Sciences Announces New CEO and Governance Changes

Cassava Sciences ( (SAVA) ) has issued an announcement.

Cassava Sciences, Inc., a biotech firm dedicated to Alzheimer’s treatment, has appointed Richard (Rick) Barry as its CEO after a comprehensive search. Barry, who joined Cassava’s board in June 2021 and became Executive Chairman in July 2024, boasts a wealth of investment management and biotech sector experience. The company also announced the separation of the CEO and Chairman roles, appointing Dr. Claude Nicaise as Chairman to align with good governance practices. Barry’s commitment to transparency and ethical practices, coupled with his focus on advancing Alzheimer’s treatment, is highlighted as Cassava anticipates results from their Phase 3 trials of the drug simufilam.

For an in-depth examination of SAVA stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskCassava Sciences’ Q3 2024: Financials and Alzheimer’s Trials Progress
TheFlyLargest borrow rate increases among liquid names
TheFlyCassava Sciences reports Q3 EPS (58c) vs. (61c) last year
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App